Program
MK-8294
A development code.
Its studies are mostly in Neoplasm Metastasis, led by Merck.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck | 11 open or running | phase 1since Jun 12, 2025 | Jun 12, 2025 | Jul 1, 2029phase 1 · NCT07030712 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 12, 2025First study: phase 1 study in Neoplasm MetastasisFirst studyNCT07030712 · 67 planned · United States, Israel, Netherlands
Ahead
- Jul 1, 2029Primary completion: phase 1 study in Neoplasm MetastasisNCT07030712
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07030712Neoplasm Metastasis · United States, Israel, Netherlands | 1 | Recruiting | Jul 1, 2029 | 67 |
How it is read
Names in the registry
- “MK-8294”, 8 entries
Codes read as this program: MK8294.
Conditions, from the studies’ own filings
- Neoplasm Metastasis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.